Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
6
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
No patent data available. Pre-approval drugs may not have Orange Book listings.
Valdyn (previously Kudeq)
Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea.
View on EMABextra
Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea. The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risk (see sections 4.3, 4.4).
View on EMAValdyn
Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea.
View on EMARayzon
For the short-term treatment of postoperative pain.The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risks (see sections 4.3, 4.4).
View on EMAVaccines, Pneumococcal
Diabetes Mellitus
Renal Transplantation
Major Depressive Disorder
Complicated Intra-abdominal Infections